Acarbose Treatment and the Risk of Cardiovascular Disease in Type 2 Diabetic Patients: A Nationwide Seven-Year Follow-Up Study

Table 2

Crude and adjusted hazard ratio of CVD with or without acarbose use.

Risk factor	Developed CVD	Did not develop CVD	Crude				Adjusted
			HR	95% CI		𝑃	HR	95% CI		𝑃
				Low	Up			Low	Up
Never use of acarbose	33203	502450	Ref.	—	—		Ref.	—	—	—
Ever use of acarbose	5081	104058	0.66	0.641	0.680	<0.001	0.99	0.958	1.019	0.443
Cumulative duration of therapy (months)
<12	4216	69976	0.83	0.802	0.855	<0.001	1.19	1.152	1.231	<0.001
12–24	545	17345	0.42	0.387	0.459	<0.001	0.70	0.643	0.762	<0.001
>24	320	16737	0.24	0.217	0.271	<0.001	0.38	0.341	0.425	<0.001
Cumulative dose (mg)
1–54,750	4373	75757	0.79	0.769	0.819	<0.001	1.14	1.105	1.18	<0.001
54,751–109,500	449	15273	0.39	0.357	0.43	<0.001	0.64	0.583	0.704	<0.001
>109,500	259	13028	0.25	0.219	0.28	<0.001	0.41	0.360	0.460	<0.001

Adjusted age, gender, other diabetic medications, and CCI. CVD: cardiovascular disease.